Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
Junek Europ-Vertrieb GmbH v Lohmann & Rauscher International GmbH & Co. KG (C-642/16)
Consideration of the question referred
30

Junek Europ-Vertrieb GmbH v Lohmann & Rauscher International GmbH & Co. KG (C-642/16)

Judgment of 17 May 2018law://eu/cjeu/2016/c-642-16/para_30@2026-11-10

30As regards the concept of ‘repackaging’, the Court has clarified that it includes the relabelling of the pharmaceutical products bearing the mark (judgment of 26 April 2007, Boehringer Ingelheim and Others, C‑348/04, EU:C:2007:249, paragraph 28).

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: Court of Justice · Fifth Chamber
Case: C-642/16 · ECLI:EU:C:2018:322
Decided: 17 May 2018
Procedure: Preliminary reference · referred by the Bundesgerichtshof (Federal Court of Justice, Germany)
Applicant: Junek Europ-Vertrieb GmbH
Defendant: Lohmann & Rauscher International GmbH & Co. KG
Rapporteur: A. Borg Barthet
Advocate General: M. Bobek
Bench: 5 judges
J.L. da Cruz Vilaça, E. Levits, A. Borg Barthet, M. Berger, F. Biltgen
Language: German
Official: CURIA · EUR-Lex 62016CJ0642

Topics

History · 1 version

17 May 2018Reading

Connections

Interprets 1: Council Regulation (EC) No 207/2009 of 26 February 2009 on the Community trade mark (codified version) (Text with EEA relevance)
Interpreted by the courts in 1: Impexeco NV and PI Pharma NV v Novartis AG and Novartis Pharma NV (C-253/20)
Cited by 4: Impexeco NV and PI Pharma NV v Novartis AG and Novartis Pharma NV (C-253/20)4 provisions; Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others (C-224/20)2 provisions; Novartis Pharma GmbH v Abacus Medicine A/S (C-147/20); Bayer Intellectual Property GmbH v kohlpharma GmbH (C-204/20)2 provisions
Cites 8: Treaty on the Functioning of the European Union (consolidated 2016); Council Regulation (EC) No 207/2009 of 26 February 2009 on the Community trade mark (codified version) (Text with EEA relevance); Bristol-Myers Squibb v Paranova A/S and C. H. Boehringer Sohn, Boehringer Ingelheim KG and Boehringer Ingelheim A/S v Paranova A/S and Bayer Aktiengesellschaft and Bayer Danmark A/S v Paranova A/S (C-427/93, C-429/93, C-436/93); Boehringer Ingelheim KG and Others v Swingward Ltd and Dowelhurst Ltd (C-348/04)2 provisions; Boehringer Ingelheim KG, Boehringer Ingelheim Pharma KG, Glaxo Group Ltd, The Wellcome Foundation Ltd, SmithKline Beecham plc, Beecham Group plc, SmithKline & French Laboratories Ltd and Eli Lilly and Co. v Swingward Ltd and Dowelhurst Ltd (C-143/00); Ferring Lægemidler A/S, acting on behalf of Ferring BV v Orifarm A/S (C-297/15); First Council Directive 89/104/EEC of 21 December 1988 to approximate the laws of the Member States relating to trade marks; Frits Loendersloot, trading as F. Loendersloot Internationale Expeditie v George Ballantine & Son Ltd and Others (C-349/95)